Autolus Therapeutics Announces FDA Approval of AUCATZYL® ( obecabtagene autoleucel - obe-cel ) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia ( r/r B-ALL )
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia ...
| Ticker |
Sentiment |
Impact |
|
AUTL
|
Neutral
|
2 %
|
|
NHPEF
|
Neutral
|
1 %
|
|
CAH
|
Neutral
|
1 %
|
